OSOlga Sanchez-Garcia

Olga Sanchez-Garcia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olga Sanchez-Garcia has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Carmen Garrido-Gimenez

    From the Maternal-Fetal Medicine Unit, Sant Pau University Hospital (C.G.-G., M.C.-L., E.L.), Universitat Autònoma de Barcelona, Spain

    1 shared publication
  • Chiara Granato

    Cardiology Department (L.G.-G., C.G., J.R.-P.) Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Spain

    1 shared publication
  • Elena Carreras-Moratonas

    Maternal-Fetal Medicine Unit Vall d'Hebron University Hospital (M.M., E.C.-M.), Universitat Autònoma de Barcelona, Spain

    1 shared publication
  • Elisa Llurba

    Department of Obstetrics and Gynecology, Maternal‐Fetal Medicine Unit, Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona Barcelona Spain

    1 shared publication
  • Jaume Alijotas-Reig

    Systemic Autoimmune Disease Unit, Department of Internal Medicine and Systemic Autoimmune Research Unit (J.A.-R.), Universitat Autònoma de Barcelona, Spain

    1 shared publication
  • Jose Rodriguez-Palomares

    Cardiology Department (L.G.-G., C.G., J.R.-P.) Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Spain

    1 shared publication

Latest Publications

  • Angiogenic Factors and Long-Term Cardiovascular Risk in Women That Developed Preeclampsia During Pregnancy

    by Carmen Garrido-Gimenez, Manel Mendoza, Monica Cruz-Lemini, Laura Galian-Gay, Olga Sanchez-Garcia, Chiara Granato, Victor Rodriguez-Sureda, Jose Rodriguez-Palomares, Elena Carreras-Moratonas, Lluis Cabero-Roura, et al.

    Preeclampsia is caused by placental impairment with increased expression of sFlt-1 (soluble fms-like tyrosine kinase 1) and decreased PlGF (placental growth factor); it has been associated with cardiovascular morbidity and mortality later in life, but the underlying mechanism remains unknown. The aim of this study was to determine whether sFlt-1 and PlGF levels during preeclampsia are associated to long-term cardiovascular risk. We prospectively recruited 43 women with previous preeclampsia and 21 controls with uncomplicated pregnancies. Cardiovascular risk assessment ≈12 years later included maternal hemodynamic, cardiac function and structure, biomarker analysis, and carotid-intima thickness evaluation. Women with previous preeclampsia had higher prevalence of hypertensive disorders and dyslipidemia than controls. In addition, they had worse global longitudinal strain, thicker left ventricular septal and posterior walls, more myocardial mass and increased carotid intima-media thickness compared with controls. PlGF during pregnancy correlated positively with high-density lipoprotein ( r =0.341; P =0.006), and negatively with global longitudinal strain ( r =−0.581; P r =−0.251; P =0.045), and mean arterial blood pressure ( r =−0.252; P =0.045), when adjusted by study group. sFlt correlated negatively with high-density lipoprotein ( r =−0.372; P =0.002) and apolipoprotein A-1 ( r =−0.257; P =0.040), and positively with carotid intima-media thickness ( r =0.269; P =0.032) and left ventricular posterior wall thickness ( r =0.368; P =0.003). The antiangiogenic state present in preeclampsia is related to greater prevalence of cardiovascular risk factors ≈12 years after delivery. The knowledge of altered angiogenic factors may help detect women with a higher risk for premature cardiovascular disease, who will require earlier follow-up after delivery.